

11. (New) The method of Claim 10, wherein said octreotide is administered topically.

12. (New) The method of Claim 11, wherein said octreotide is administered in the form of an ophthalmic liquid preparation.

13. (New) The method of Claim 10, wherein said octreotide is administered subcutaneously.

14. (New) A method for the topical treatment of macular edema comprising topically administering to a patient a somatostatin analog which binds to at least one somatostatin receptor in the eye, wherein said somatostatin analog is a polypeptide, and wherein said somatostatin analog is in the form of an ophthalmic liquid preparation.

15. (New) The method of Claim 14, wherein said ophthalmic liquid preparation is in the form of eye drops, an eye gel or an eye ointment.

16. (New) The method of Claim 14, wherein said somatostatin receptor is an hSST-2 receptor.

17. (New) The method of Claim 14 wherein the somatostatin analog is an octreotide.

18. (New) A method for the topical treatment of diabetic retinopathy comprising topically administering to a patient an octreotide, wherein the octreotide binds to at least one somatostatin receptor in the eye, and wherein the octreotide is in the form of an ophthalmic liquid preparation.